Managing Director Joint: Managing

Managing Director

Prabhakar R. Dalal

Independent Director

Dr. Anjana Grewal

Independent Director

Madhusudan B. Agrawal

Vice Chairman

Chandrakant M. Khetan

Independent Director

Yogesh M. Agrawal: Managing

Dear Shareholders,

Your Directors are pleased to present their Forty-Third Annual Report and Audited Financial Statements for the Year ended

31 March 2022.

(` in cr. except EPS)

Particulars

consolidated

Standalone

year ended 31 march

2022

2021

2022

2021

Revenue from operations

3,341

2,890

3,141

2,719

Other Income

116

26

140

104

Profit before Depreciation, Finance Costs and Tax expense

1,045

1,025

1,031

1,020

Profit after Tax

713

654

720

676

Total Comprehensive Income

705

647

720

674

Earning Per Share (EPS) (`) (Basic)

82.45

75.09

83.28

77.59

The Financial Statements for the year ended 31 March 2022 have been prepared in accordance with the Indian Accounting

Standards (Ind AS) read with Section 133 and other applicable provisions of the Companies Act, 2013 (“Act”).

The Company discloses consolidated and standalone financial results on a quarterly basis, which are subjected to limited review,

and publishes consolidated and standalone audited financial results annually.

The Company continues to be engaged in development, manufacture and sale of branded and generic pharmaceutical

formulations.

During the year under review, Consolidated Revenue from Operations increased to ` 3,341 cr., around 16% higher than the

previous year. Consolidated Profit After Tax grew at 9% from ` 654 cr. to ` 713 cr. Exports contributed around 70% of the business.

financial PErformancE

PErformancE rEviEw

consolidated revenue from

operations

(` cr.)

16%

FY2022

3,341

FY2021

2,890

Consolidated Profit after Tax

(` cr.)

9%

FY2022

713

FY2021

654:

Managing Director; Mr. Rajesh

M. Agrawal, Joint: Managing

Managing Director

Joint: Managing

Managing Director

Chairman of the CSR Committeee

Mumbai, 10 May 2022:

letter of even date which is

annexed and forms an integral part of this report.:

letter.

1.

The compliance of provisions of all laws, rules, regulations, standards applicable to ajanta Pharma limited (hereinafter

called ‘the Company’) is the responsibility of the management of the Company. Our examination was limited to the

verification of records and procedures on test check basis for the purpose of issue of the Secretarial Audit Report.

2.

Maintenance of secretarial and other records of applicable laws is the responsibility of the management of the Company.

Our responsibility is to issue Secretarial Audit Report, based on the audit of the relevant records maintained and furnished

to us by the Company, along with explanations where so required.

3.

We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the

correctness of the contents of the secretarial and other legal records, legal compliance mechanism and corporate conduct.

Further part of the verification was done on the basis of electronic data provided to us by the Company due to COVID-19

Pandemic restrictions and on test check basis to ensure that correct facts as reflected in secretarial and other records

produced to us. We believe that the processes and practices we followed, provides a reasonable basis for our opinion for

the purpose of issue of the Secretarial Audit Report.

4.

We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.

5.

Wherever required, we have obtained the management representation about list of applicable laws, compliance of laws,

rules and regulations and major events during the audit period.

6.

The Secretarial Audit Report is neither an assurance as to the future viability of the Company nor of the efficacy or

effectiveness with which the management has conducted the affairs of the Company.

annExurE to SEcrEtarial audit rEPort

Annexure - “C” to the Directors’ Report - Secretarial

Audit Report

For alwyn d’Souza & co.

Company Secretaries

alwyn P d’Souza

FCS. 5559

Place: Mumbai

C.P. No. 5317

Date: 10 May 2022

udin: F005559D000296201:

Managing Director

396:1

27.26% @

(iv)

Mr. Rajesh M. Agrawal, Joint: Managing

Managing Director (“MD”). The Board has complete

access to any information within the Company.

Agenda papers with minutes of previous meeting,

committee meetings & meetings of subsidiary

companies as also other information/proposals

with detailed notes/background information with

applicable regulatory provisions and requisite

disclosures, are circulated at least 7 days prior to

the meeting, thereby enabling the Board to take

decisions on an informed basis.

Apart from the Board members, the Chief Financial

Officer (“CFO”) and the Company Secretary attend

all the Board Meetings. Detailed presentation is

made by the Management in each meeting to

apprise the Board of important developments

in the industry, business segments, operations,

capex, sales & marketing, products, HR initiatives,

important developments in subsidiaries, regulatory

changes etc. Other senior management executives

are invited as and when necessary or to familiarise

the Board with critical aspects of respective

functions.

During the year, five Board Meetings were held

on 30 April 2021; 29 July 2021; 29 October

2021, 28 December 2021 and 31 January 2022.

Composition of Directors, their other directorships

& committee memberships and their attendance in

Board / Annual General Meeting (“AGM”) during the

financial year, are given below::

Managing Director, Joint Managing

Director & CFO. The Company uploads on its website

transcript and audio recordings of such calls on a

voluntary basis.

website:

The Company’s website (www. ajantapharma.com)

contains a separate dedicated section ‘Investors’ wherein

information appropriate for shareholders is available. It

displays vital information relating to the Company and

its performance, official press releases, presentation

to analysts, investor call transcripts, policies & codes,

shareholding patterns and other material information

relevant to shareholders. The Company’s Annual

Reports are also available in downloadable form.

annual report:

The Annual Report containing, inter-alia, Audited

Standalone Financial Statements, Audited Consolidated

Financial Statements, Directors’ Report, Auditors’ Report

and other important information is circulated to members

and others entitled to. The Management Discussion and

Analysis (MDA) Report forms part of the Annual Report.

As a part of the green initiative, the Annual Reports are

sent by e-mail to the Shareholders whose e-mail IDs are

registered with the Depositories / Registrar & Transfer

Agent (“RTA”). If any member wishes to get a duly

printed copy of the Annual Report, the Company sends

the same, free of cost, upon receipt of request from the

member.

reminders to Shareholders for unclaimed shares /

dividend:

The Company sends reminders to all those shareholders

whose unclaimed dividend / shares are liable to be

transferred to the Investor Education and Protection

Fund (“IEPF”) account.

filing with the Stock Exchanges:

All other submission to be made to the Stock Exchanges

viz., shareholding pattern, corporate governance report,

press releases, statement of investor complaints, are

filed electronically with the BSE Limited and the National

Stock Exchange of India Limited.

investors:

To serve the investors better and as required under

Regulation 46(2)(j) of the Listing Regulations, the

Company’s Grievance Redressal Division has a

designated email address for investor complaints,

investorgrievance@ajantapharma.com. The Company’s

Compliance Officer monitors this email regularly.

Material developments related to the

Company

that

are

potentially

price-

sensitive in nature in accordance with

Regulation 30 of the Listing Regulations,

are also disclosed to the Stock Exchanges

as per the Policy for Disclosure of Material

Information. They are also made available

on Company’s website.:

Managing Director

01/04/2008

4

Rajesh Mannalal Agrawal

00302467

Whole time Director

30/04/2013

5

Chandrakant Mohanlal Khetan

00234118

Director

20/10/2008

6

Prabhakar Ramchandra Dalal

00544948

Director

13/06/2014

7

Viswanathan Hariharan Kalpati

06563472

Director

30/04/2013

8

Dr. Anjana Grewal

06896404

Director

13/06/2014

Ensuring the eligibility for the appointment / continuity of every Director on the Board is the responsibility of the management

of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an

assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has

conducted the affairs of the Company.

For alwyn d’Souza & co.

Company Secretaries

alwyn d’Souza

FCS No. 5559

Place: Mumbai

C. P. No. 5137

Date: 10 May 2022

udin: F005559D000296234:

Managing Director and Mr. Arvind Agrawal, Chief Financial Officer hereby certify for the financial year

ended 31 March 2022 that:

(a) We have reviewed IND AS financial statements and the cash flow statement for the year and that to the best of our knowledge

and belief:

(i)

these statements do not contain any materially untrue statement or omit any material fact or contain statements that

might be misleading;

(ii)

these statements together present a true and fair view of the company’s affairs and are in compliance with IND AS,

applicable laws and regulations.

(b) There are, to the best of our knowledge and belief, no transactions entered into by the Company during the year which are

fraudulent, illegal or violative of the company’s code of conduct.

(c) We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated

the effectiveness of internal control systems of the company pertaining to financial reporting and we have disclosed to the

auditors and the Audit Committee, deficiencies in the design or operation of such internal controls, if any, of which we are

aware and the steps we have taken or propose to take to rectify these deficiencies.

(d) We have indicated to the auditors and the Audit committee:

(i)

that there are no significant changes in internal control over financial reporting during the year;

(ii)

that there are no significant changes in accounting policies during the year; and

(iii) that there are no instances of significant fraud of which we have become aware.

For ajanta Pharma limited

yogesh m. agrawal

Mumbai, 10 May 2022: Managing

Managing Director

Joint: Managing

Managing Director

Joint: Managing

Managing Director

Joint: Managing

Managing Director

Joint: Managing

Letter of Offer was made to all eligible shareholders.

The Company bought back 11,20,000 equity shares out of the shares that were tendered by eligible shareholders and

extinguished the equity shares bought back on 28 February 2022. The Company has utilised its Securities Premium

(` 0.54 Crore) and General Reserve (` 285.06 Crore) for the buyback of its equity shares. Total transaction cost of ` 2.02

Crore incurred towards buyback and tax of ` 66.48 Crore was offset from retained earnings. In accordance with Section 69

of the Companies Act 2013, the Company has created Capital Redemption Reserve of ` 0.22 Crore equal to the nominal

value of the shares bought back as an appropriation from the General Reserve.:

Letter of Offer was made to all eligible shareholders.

The Company bought back 735,000 equity shares out of the shares that were tendered by eligible shareholders and

extinguished the equity shares bought back on 30 December 2020. The Company has utilised its Securities Premium

(` 1.63 Crore) and General Reserve (` 134.35 Crore) for the buyback of its equity shares. Total transaction cost of ` 0.78

Crore incurred towards buyback and tax of ` 31.64 Crore was offset from retained earnings. In accordance with Section 69

of the Companies Act 2013, the Company has created Capital Redemption Reserve of ` 0.15 Crore equal to the nominal

value of the shares bought back as an appropriation from the General Reserve.

22.9 details of equity Shares held by promoters at the end of the year

` in Crore

name of Shareholders

As at 31 March 2022

As at 31 March 2021

number of

Shares

% holding

% Change

during the

year

number of

Shares

% holding

% Change

during the

year

Yogesh M. Agrawal, trustee Yogesh

Agrawal Trust

12,380,262

14.49

(1.22) 12,533,346

14.48

(0.85)

Rajesh M. Agrawal, trustee Rajesh

Agrawal Trust

12,380,262

14.49

(1.22) 12,533,345

14.48

(0.84)

Ravi P. Agrawal, trustee Ravi Agrawal

Trust

12,276,207

14.37

(1.26) 12,433,113

14.37

(0.89)

Aayush M. Agrawal, trustee Aayush

Agrawal Trust

12,261,811

14.36

(1.30) 12,423,429

14.36

(0.93)

Gabs Investments Private Limited

8,392,262

9.83

-

8,392,262

9.70

-

Ganga Exports being represented by

Mr. Yogesh M. Agrawal, Mr. Rajesh M.

Agrawal & Mr. Ravi P. Agrawal

2,299,852

2.69

(1.90)

2,344,328

2.71

(1.95)

Ravi P. Agrawal

190,000

0.22

-

190,000

0.22

-

Aayush M. Agrawal

20,000

0.02

-

20,000

0.02

-

23. otheR equity

` in Crore

Particulars

As at

31 March 2022

As at

31 March 2021

Capital redemption reserve

Balance at the beginning of the year

2.40

2.25

Add: amount transferred upon buyback of shares

0.23

0.15

Balance as at the year end

2.63

2.40

Securities premium account

Balance at the beginning of the year

-

1.06

Add: addition during the year

0.54

0.58

Less: utilisation for buyback of shares

(0.54)

(1.64)

Balance as at the year end

-

-

Foreign Currency translation Reserve

Balance at the beginning of the year

9.20

14.32

Add: Addition during the year

(8.33)

(5.12)

Balance as at the year end

0.87

9.20

general reserve

Balance at the beginning and at the end of the year

816.83

951.18:

Managing Director

Mr. Rajesh M. Agrawal

Joint: Managing

Managing Director

Joint: Managing

Managing Director

Joint: Managing

Managing Director

Joint: Managing

Managing Director

Joint: Managing

Managing Director

Joint: Managing

Letter of Offer was made to all eligible shareholders.

The Company bought back 11,20,000 equity shares out of the shares that were tendered by eligible shareholders and

extinguished the equity shares bought back on 28 February 2022. The Company has utilised its Securities Premium

(` 0.54 Crore) and General Reserve (` 285.06 Crore) for the buyback of its equity shares. Total transaction cost of ` 2.02

Crore incurred towards buyback and tax of ` 66.48 Crore was offset from retained earnings. In accordance with Section 69

of the Companies Act 2013, the Company has created Capital Redemption Reserve of ` 0.22 Crore equal to the nominal

value of the shares bought back as an appropriation from the General Reserve.

Previous year

The Board of Directors of the Company, at its meeting held on 3 November 2020 had approved a proposal to buyback

upto 7,35,000 equity shares capital, of the Company for an aggregate amount not exceeding ` 135.98 Crore being 0.84%

of the total paid up equity share capital at ` 1,850 per equity share. A: Letter of Offer was made to all eligible shareholders.

The Company bought back 7,35,000 equity shares out of the shares that were tendered by eligible shareholders and

extinguished the equity shares bought back on 30 December 2020. The Company has utilised its Securities Premium

(` 1.63 Crore) and General Reserve (` 134.35 Crore) for the buyback of its equity shares. Total transaction cost of ` 0.78

Crore incurred towards buyback and tax of ` 31.64 Crore was offset from retained earnings. In accordance with Section 69

of the Companies Act 2013, the Company has created Capital Redemption Reserve of ` 0.15 Crore equal to the nominal

value of the shares bought back as an appropriation from the General Reserve.

21.9 details of equity shares held by promoters at the end of the year

name of Promoter

As at 31 march 2022

As at 31 march 2021

number of

Shares

% of total

shares

% change

during the

year

number of

Shares

% of total

shares

% change

during the

year

Yogesh M Agrawal, trustee Yogesh

Agrawal Trust

12,380,262

14.49

(1.22) 12,533,346

14.48

(0.84)

Rajesh M Agrawal, trustee Rajesh Agrawal

Trust

12,380,262

14.49

(1.22) 12,533,345

14.48

(0.84)

Ravi Purushottam Agrawal, trustee Ravi

Agrawal Trust

12,276,207

14.37

(1.26) 12,433,113

14.37

(0.89)

Aayush Madhusudan Agrawal, trustee

Aayush Agrawal Trust

12,261,811

14.36

(1.30) 12,423,429

14.36

(0.93)

Gabs Investments Private Limited

8,392,262

9.83

-

8,392,262

9.70

-

Ganga Exports being represented by Mr.

Yogesh Agrawal, Mr. Rajesh Agrawal &

Mr. Ravi Agrawal

2,299,852

2.69

(1.90)

2,344,328

2.71

(1.95)

Ravi P. Agrawal

190,000

0.22

-

190,000

0.22

-

Aayush M. Agrawal

20,000

0.02

-

20,000

0.02

-

Notes to the Standalone Financial Statements

as at 31 march 2022

Managing Director

Mr. Rajesh M. Agrawal

Joint: Managing

Managing Director

Mr. Aayush M. Agrawal

Mr. Ravi P. Agrawal

B)

the following transactions were carried out with related parties:

` in Crore

Sr.

no

Particulars

category

year ended

31 march 2022

year ended

31 march 2021

1.

Sale of goods

APML

I

96.41

181.80

APPI

I

139.34

142.52

APMIL

I

-

0.45

APUI

I

580.07

614.43

2.

Purchase of capital goods

APML

I

0.17

-

3.

dividend from Subsidiary companies

APML

I

-

53.03

APPI

I

22.33

30.18

4.

expenses Reimbursement to

APUI

I

-

3.23

APNL

I

0.25

0.50

5.

compensation to Key management and others

Short term employee Benefits

Mr. Madhusudan B. Agrawal

II

3.42

2.97

Mr. Yogesh M. Agrawal

II

11.06

9.59

Mr. Rajesh M. Agrawal

II

11.06

9.59

Mr. Arvind Agrawal

II

1.43

1.31

Mr. Gaurang C. Shah

II

0.76

0.64

Ms. Tanya Agrawal

IV

0.08

0.07

post-employment benefits

II & IV

0.62

0.37

6.

commission to executive director

Mr. Yogesh M. Agrawal

II

5.25

3.27

Mr. Rajesh M. Agrawal

II

5.25

3.27

7.

commission and Sitting fees to non-executive director

Mr. Mannalal B. Agrawal

II

0.06

0.05

Mr. Chandrakant M. Khetan

II

0.10

0.09

Mr. K. H. Viswanathan

II

0.08

0.07

Mr. Prabhakar Dalal

II

0.07

0.07

Dr. Anjana Grewal

II

0.06

0.06

8.

dividend Paid

Key Management Personnel

II

0.03

0.03

Others

III & IV

57.83

58.45

9.

commission from Subsidiary on corporate guarantee

APUI

I

0.52

0.46:

Managing Director

Joint: Managing

letter etc. with attested specimen

signature of the duly authorised signatory(ies)

who are authorised to vote, to the Scrutinizer

by e-mail to scrutinizer@ajantapharma.com

with a copy marked to helpdesk.evoting@

cdslindia.com

•

Alternatively Non Individual shareholders

are required to send the relevant Board

Resolution/ Authority: letter etc. together

with attested specimen signature of the duly

authorised signatory who are authorised to

vote, to the Scrutinizer and to the Company

at the email address viz.; scrutinizer@

ajantapharma.com

&

investorgrievance@

ajantapharma.com, if they have voted from

individual tab & not uploaded same in the

CDSL e-voting system for the scrutinizer to

verify the same.

If you have any queries or issues regarding

attending AGM & e-voting from the CDSL e-voting

System, you can write an email to helpdesk.

evoting@cdslindia.com or contact on toll free

no.- 1800 22 55 33. All grievances connected with

the facility for voting by electronic means may be

addressed to Mr. Rakesh Dalvi, Manager, Central

Depository Services (India) Limited, A Wing, 25th

Floor, Marathon Futurex, Mafatlal Mill Compounds,

N M Joshi Marg, Lower Parel (East), Mumbai -

400 013 or send an email to helpdesk.evoting@

cdslindia.com or call on toll free no.- 1800 22 55

33.

13. Instructions for Shareholders attending the AGM

through VC / OAVM & e-voting during Meeting are as

under:

i.

The procedure for attending meeting & e-voting

on the day of the AGM is same as the instructions

mentioned above for remote e-voting.

ii.

The link for VC / OAVM to attend meeting will

be available where the EVSN of Company will

be displayed after successful login as per the

instructions mentioned above for remote e-voting.

iii.

Shareholders are encouraged to join the Meeting

through Laptops / IPads for better experience.

iv.

Further shareholders will be required to allow

camera and use internet with a good speed to

avoid any disturbance during the meeting.

v.

Please note that participants connecting from

mobile devices or tablets or through laptop

connecting via mobile hotspot may experience

audio/video loss due to fluctuation in their

respective network. It is therefore recommended

to use stable Wi-Fi or LAN connection to mitigate

any kind of aforesaid glitches.

vi.

Shareholders who would like to express their views

ask questions during the meeting may register

themselves as a speaker by sending their request

in advance during Saturday, 30 July 2022 (9:00

a.m. IST) to Tuesday, 2 August 2022 (5:00 p.m.

IST)

to

investorgrievance@ajantapharma.com

mentioning their name, demat account number /

folio number, email id, mobile number and PAN.

Shareholders who do not wish to speak during the

AGM but have queries may send their queries to

investorgrievance@ajantapharma.com 5 days prior

to meeting mentioning their name, demat account

number / folio number, email id, mobile number, PAN

and the query. These queries will be replied suitably

by email.

vii. Those

shareholders

who

have

registered

themselves as a speaker will only be allowed to

express their views / ask questions during the

meeting. Company reserves the right to restrict the

number of speakers depending on the availability

of time during the AGM.

viii. Only those shareholders, who are present in

the AGM through VC / OAVM facility and have

not casted their vote on the resolutions through

remote e-voting and are otherwise not barred from

doing so, shall be eligible to vote through e-voting

system available during the AGM.

ix.

If any votes are cast by the shareholders through

the e-voting available during the AGM and if the

same shareholders have not participated in the

meeting through VC / OAVM facility, then the votes

